Page 10 - Dupilumab Development Programdupilumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dupilumab development programdupilumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dupilumab Development Programdupilumab Today - Breaking & Trending Today

Dupilumab Proven Effective in Treating Patients With Severe Asthma, Study Finds

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab.
....

Nasal Polyps ,

Study Compares Biologics Omalizumab, Mepolizumab, and Dupilumab for Asthma

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. ....

Atopic Dermatitis Treatment Is Still More Trial and Error Than Personalized: Dr Emma Guttman-Yassky

While the future is bright with potential for personalized medicine to treat atopic dermatitis, current treatment is still more like trial and error, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai. ....

Emma Guttman Yassky , Laboratory For Inflammatory Skin Diseases , Icahn School Of Medicine At Mount Sinai , Waldman Professor , System Chair , Icahn School , Mount Sinai , Occupational Dermatitis Clinic , Inflammatory Skin , Personalized Medicine , Jak Inhibitor ,

Prurigo Nodularis Improves Following Treatment With Dupilumab

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.

....

Global Assessment , Skin Lesions , Prurigo Nodularis , Immunoglobulin E ,

Ruxolitinib Cream Has Lower Number Needed to Treat for AD Compared With Other Therapies

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023. ....

Global Assessment , Eczema Area , Severity Index , Ruxolitinib Cream , Atopic Dermatitis , Number Needed To Treat ,